HRP20240118T1 - Disperzivni pripravci - Google Patents

Disperzivni pripravci Download PDF

Info

Publication number
HRP20240118T1
HRP20240118T1 HRP20240118TT HRP20240118T HRP20240118T1 HR P20240118 T1 HRP20240118 T1 HR P20240118T1 HR P20240118T T HRP20240118T T HR P20240118TT HR P20240118 T HRP20240118 T HR P20240118T HR P20240118 T1 HRP20240118 T1 HR P20240118T1
Authority
HR
Croatia
Prior art keywords
preparation
pharmaceutically acceptable
amino
granules
active ingredient
Prior art date
Application number
HRP20240118TT
Other languages
English (en)
Croatian (hr)
Inventor
Harshad PATANKAR
Nicolaas Martha Felix Goyvaerts
Gopal Rajan RANGA RAJAN
Original Assignee
Janssen Sciences Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Company filed Critical Janssen Sciences Ireland Unlimited Company
Publication of HRP20240118T1 publication Critical patent/HRP20240118T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
HRP20240118TT 2016-10-24 2017-10-23 Disperzivni pripravci HRP20240118T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions
EP17794275.2A EP3528791B1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Publications (1)

Publication Number Publication Date
HRP20240118T1 true HRP20240118T1 (hr) 2024-04-12

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240118TT HRP20240118T1 (hr) 2016-10-24 2017-10-23 Disperzivni pripravci

Country Status (21)

Country Link
US (2) US11065198B2 (enExample)
EP (2) EP3528791B1 (enExample)
JP (2) JP7197474B2 (enExample)
KR (2) KR102861006B1 (enExample)
CN (1) CN110191704A (enExample)
CA (1) CA3039562A1 (enExample)
DK (1) DK3528791T3 (enExample)
ES (1) ES2970870T3 (enExample)
FI (1) FI3528791T3 (enExample)
HR (1) HRP20240118T1 (enExample)
HU (1) HUE064823T2 (enExample)
LT (1) LT3528791T (enExample)
MA (1) MA46563B1 (enExample)
MX (1) MX2019004767A (enExample)
PL (1) PL3528791T3 (enExample)
PT (1) PT3528791T (enExample)
RS (1) RS65159B1 (enExample)
SI (1) SI3528791T1 (enExample)
SM (1) SMT202400060T1 (enExample)
TW (1) TWI821163B (enExample)
WO (1) WO2018077815A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114126655A (zh) * 2019-07-03 2022-03-01 爱尔兰詹森科学公司 用利匹韦林治疗儿科患者的hiv的方法
JP2023503403A (ja) 2019-11-29 2023-01-30 シピオ ライフ サイエンシズ リミテッド リルピビリンを含む組成物及び腫瘍又は癌を治療するためのその使用
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2003266413B2 (en) 2002-08-09 2009-04-02 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
CN101068597B (zh) * 2004-09-02 2012-04-18 詹森药业有限公司 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
CN104586850A (zh) 2004-09-02 2015-05-06 詹森药业有限公司 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐
PL1632232T6 (pl) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
SI3366278T1 (sl) 2006-06-23 2024-12-31 Janssen Sciences Ireland Unlimited Company Vodne suspenzije tmc278
WO2015120014A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
WO2015176008A1 (en) 2014-05-16 2015-11-19 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Also Published As

Publication number Publication date
RU2019115672A3 (enExample) 2021-01-21
PT3528791T (pt) 2024-02-19
DK3528791T3 (da) 2024-01-29
SMT202400060T1 (it) 2024-03-13
KR20190073450A (ko) 2019-06-26
TWI821163B (zh) 2023-11-11
HUE064823T2 (hu) 2024-04-28
CN110191704A (zh) 2019-08-30
WO2018077815A1 (en) 2018-05-03
BR112019007564A2 (pt) 2019-07-02
MA46563A (fr) 2019-08-28
CA3039562A1 (en) 2018-05-03
SI3528791T1 (sl) 2024-04-30
RS65159B1 (sr) 2024-02-29
JP2023011659A (ja) 2023-01-24
EP3528791B1 (en) 2023-12-06
RU2019115672A (ru) 2020-11-24
KR20240011873A (ko) 2024-01-26
TW201828927A (zh) 2018-08-16
MX2019004767A (es) 2019-07-01
EP3528791A1 (en) 2019-08-28
EP4248947A2 (en) 2023-09-27
JP7197474B2 (ja) 2022-12-27
PL3528791T3 (pl) 2024-04-02
ES2970870T3 (es) 2024-05-31
US20220008333A1 (en) 2022-01-13
FI3528791T3 (fi) 2024-01-30
KR102861006B1 (ko) 2025-09-16
MA46563B1 (fr) 2024-01-31
US20200069579A1 (en) 2020-03-05
LT3528791T (lt) 2024-05-27
EP4248947A3 (en) 2023-11-22
US11065198B2 (en) 2021-07-20
JP2020500168A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
HRP20240118T1 (hr) Disperzivni pripravci
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
HRP20150798T4 (hr) Kombinacije pirimidina koje sadrže nnrti s inhibitorima rt
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
CA2484184A1 (en) Minoxidil foam formulation
NO2017063I1 (no) Kombinasjon av: - rilpivirine hydroklorid etter en terapeutisk ekvivalent form derav, - emtricitabine og - tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat
RU2015124694A (ru) Саморегулируемое высвобождение фармацевтического ингредиента
WO2015120110A3 (en) Novel pharmaceutical formulations
HRP20100577T1 (hr) Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti
WO2011147026A3 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
HRP20200255T1 (hr) Formulacija ac220 osušena raspršivačem
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
BRPI0620063B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
HRP20231670T1 (hr) Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol
BR112015020443A8 (pt) formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica
JP2020500168A5 (enExample)
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
HRP20221344T1 (hr) Novi pripravak acetaminofenskog spoja bez nuspojave po jetru
HK1209027A1 (en) Vesicular formulations, uses and methods
NO20071720L (no) Fumarat av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril.
WO2020086705A3 (en) Pharmaceutical compositions and methods of making on demand solid dosage formulations
UA92469C2 (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
WO2012060594A3 (ko) 티오우레아계 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항염증 조성물